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Abstract. – OBJECTIVE: Although human pa-
pillomavirus (HPV) infection has been studied
extensively in women, data on male infection are
limited. The purpose of this study was to investi-
gate persistence of HPV infection at multiple
genital sites in men and to define potential asso-
ciations with socio-behavioural characteristics.
PATIENTS AND METHODS: Penile, urethral
and seminal specimens were tested by the INNO-
LiPA HPV system (Innogenetics) and a PCR as-
say. Persistence was defined as the detection of
the same HPV type at ≥ 2 consecutive visits. The
Kaplan-Meier method and the log-rank test were
applied to estimate the likelihood of persistence.
RESULTS: A total of 50 men (median age: 33
years) were followed for a median of 14.7
months. Altogether, 49%, 36%, 26% and 11% of
baseline HPV-positive men had 6-, 12-, 18- and
24-month persistent infection with any HPV
type, respectively. The 6-, 12- and 18- month per-
sistence was more common for oncogenic HPV
infections; 24-month persistence was similar.
The median duration of persistence was 21.7
months for any HPV. The median duration of
persistence for any HPV type was significantly
longer in the penile sample (22.5 months, 95%
CI: 18.3-26.7) than the semen sample (15.3
months, 95% CI: 14.5-16.1). 
CONCLUSIONS: Over a third of type-specific
HPV infections in men remained persistent over
a 24-month period. The median duration of HPV
infection was longer in penile samples com-
pared to seminal samples. With increasing at-
tention on HPV vaccination as a potential pre-
ventive approach for men, it is imperative to ob-
tain additional insight on natural history of HPV
infection in men, particularly as far as incidence
and duration are concerned.
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Introduction
Human papillomavirus (HPV) is the most
common sexually transmitted viral infection and
is associated with ano-genital and oral disease in
women and men1,2. There are approximately 45
HPV types that infect the genital mucosa and are
classified as oncogenic or non-oncogenic HPV
types on the basis of their association with pre-
malignant and malignant genital lesions3. In
women, most HPV infections are asymptomatic
and clear spontaneously within 1-2 years4; how-
ever, some oncogenic infections persist and are
etiologically linked with cervical cancer5,6. 
In contrast with the wealth of data available in
women, much less is known about HPV infection
in men. However, since the risk of HPV infection
and cervical cancer in females is significantly in-
fluenced by male sexual behaviour7, a greater un-
derstanding of the natural history of HPV infec-
tion in men is critical in cervical cancer preven-
tion. This knowledge is also needed to inform
policy decisions concerning the prevention and
treatment of HPV-related disease in men, e.g.
cost-effectiveness models for HPV vaccination. 
The persistence of genital HPV infection in
men has been evaluated in few prospective stud-
ies6-11. Most of these studies have examined pe-
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nile HPV infection. However, since HPV infec-
tion in men is often multifocal, information on
the characteristics of infections at multiple geni-
tal sites can provide insight on the dynamics of
genital HPV infection in men8,14,15. In addition,
given the wide heterogeneity of HPV types in-
fecting the male genital tract16,17, and the variable
sensitivity of different molecular methods avail-
able for HPV detection and typing18,19, the com-
bined use of complementary testing methods
might considerably improve the sensitivity of
HPV detection.
The current study investigated the persistence
of type-specific HPV infection at multiple genital
sites over a 24-month period using a combination
of two highly-sensitive HPV testing methods and
then examined the potential association with se-
lected socio-behavioural characteristics.
Patients and Methods
Study Population
From January 2006 through April 2007, par-
ticipants were recruited from men who requested
an HPV test at the Unit of Virology of the De-
partment of Sciences for Health Promotion and
Mother and Child Care (Polyclinic, Palermo Uni-
versity, Palermo, Italy). The common reasons for
requesting an HPV test included having an HPV-
positive partner or having a risky sexual contact
in the prior 2 months. A total of 65 men aged 18
years or older who tested HPV DNA positive
were subsequently invited to participate in a lon-
gitudinal study of HPV infection in men. Men
were enrolled in the study if they planned to stay
in the area for the next 2 years, consented to a
medical and sexual history interview and a geni-
tal sampling at each study visit for a maximum
of 2 years, and agreed to be re-sampled in cases
of any initially inadequate genital sampling, as
indicated by the absence of β-globin in the geni-
tal DNA sample. Participants were followed at 6-
month intervals until clearance of existing HPV
infection or for a maximum of 24 months
whichever came first. All participants gave writ-
ten consent prior to entering the study. The in-
formed consent and the study protocol were ap-
proved by the institutional Review Board at the
Polyclinic, Palermo University (Italy).
Data Collection and Genital Sampling
At each study visit, the study clinicians ad-
ministered a medical and sexual-history inter-
view to collect information on sociodemograph-
ic characteristics, reproductive history and sexu-
al behaviour. In addition, a genital examination
was performed to identify signs of flat, macular,
papular, and acuminate lesions. For HPV sam-
pling, patients were instructed to avoid washing
their genitalia the day before the examination
and to observe 2 days of sexual abstinence be-
fore the examination. Three samples were col-
lected from penis, urethra and semen. Genital
sampling was performed as described previous-
ly14, with some modifications. In brief, for penile
sampling, cells from the dorsal/ventral surface
of the shaft were collected by a standard-sized,
dry Dacron swab first, and then by a saline-wet-
ted Dacron swab. Cells from the inner foreskin,
coronal sulcus, frenulum and glans were also
collected using a saline-wetted cytobrush. Five
to six back-and-forth movements of the
swab/cytobrush were performed at each penile
site. All penile cells were subsequently com-
bined and placed in a vial with 3 ml of phos-
phate-buffered saline. For urethral sampling, a
very thin, saline-wetted cytobrush was inserted
1.5 cm into the urethra, rotated 360 degrees, and
removed. The urethral cells were placed in a
separate vial with 3 ml of phosphate-buffered
saline. The semen sample was obtained through
participant self-masturbation and placed in ster-
ile containers. If the sample was obtained at
home, men were asked to transfer the sample to
the laboratory within 2 hours after ejaculation.
All three samples were processed for DNA ex-
traction immediately following collection.
DNA Extraction and HPV Testing
Cells obtained from penile brushing and ure-
thral brushing were spun down at 13,000 rpm for
5 min and total DNA was extracted with the use
of the High Pure PCR Template Preparation kit
(Roche Diagnostics GmbH, Mannheim, Ger-
many), following manufacturer’s instructions. The
semen samples were maintained at room tempera-
ture until complete liquefaction (if the sample was
very viscous, it was maintained at 37°C for 10 to
15 min). Two aliquots of 200 µl of semen were
then extracted by using the same kit as for the pe-
nile and urethral samples (Roche), except that the
incubation for proteinase K digestion was at 56°C
for 60 min and the final elution in 100 µl.
DNA quality and the absence of inhibitors
were confirmed by testing for the human β-glo-
bin gene, as described elsewhere14. If a partici-
pant was negative for β-globin, he was resam-
pled within one week, resulting in all men being
β-globin positive.
Amplifications were carried out in a DNA ther-
mal cycler (Mastercycler, Eppendorf, Hamburg,
Germany) and the PCR products were analyzed in
8% polyacrylamide gel. The presence of HPV
DNA was detected using two HPV assays. Initial-
ly, the INNO-LiPA HPV Genotyping kit (Inno-
genetics N.V., Ghent, Belgium), based on the
combined use of SPF10 PCR and LiPA hybridica-
tion20, was employed. The SPF general primers
detect at least 43 different HPV genotypes20 and
the LiPA type-specific assay identifies twenty-
eight types. Due to the higher number of HPV
types detected by the SPF10 primers than the LiPA
assay, some samples yielded SPF10-positive/LiPA-
negative results. These HPV types were subse-
quently amplified by a highly sensitive nested
PCR assay, consisting of a first step of amplifica-
tion with the MY09/11 primer pair, followed by
the second step with the GP05+/GP06+ primers,
as previously described18. The HPV genotyping
procedure was based on the direct sequencing of
MY/GP-PCR fragments, utilizing consensus nest-
ed primers as sequencing primers, as described
elsewhere18. Briefly, the amplification products
were purified by Microcon YM-100 Filter De-
vices (Amicon; Millipore, Billerica, MA, USA),
and approximately 5 ng of product was added to 4
µl of BigDyeTM Terminator Ready Reaction mix
(Applied Biosystems, Foster City, CA, USA). The
purification of reaction mixtures and removal of
free BigDyeTM was performed by Centrisep Spin
Columns (Princeton Separations, Adelphia, NJ,
USA) and the mixture was analyzed on an ABI
PRISM1 310 Genetic Analyzer (Applied Biosys-
tems). Alignments were obtained from the online
BLAST server.
Statistical Analysis
HPV types were classified by their oncogenic
potential3,6 with 17 types classified as oncogenic
HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53,
56, 58, 59, 66, 68, 70 and 73), and the rest classi-
fied as non-oncogenic types. Oncogenic infec-
tions were defined as infections with oncogenic
HPV types, regardless of co-infection with non-
oncogenic types, and further divided to infec-
tions with a single or multiple oncogenic types.
Non-oncogenic HPV infections are comprised of
infection with a single or multiple non-oncogenic
genotypes only.
Persistence of type-specific HPV infection
was defined as the detection of the same HPV
genotype in the same subject in 2 or more con-
secutive visits, regardless of the anatomical ori-
gin of the samples. Persistent infections that were
either first detected at the baseline or acquired
during the follow-up were included. It was clas-
sified as 6-, 12-, 18- or 24- month persistence ac-
cording to the minimal length of HPV presence
in the same subject. Overlapping persistence cat-
egories were used, and men with longer-term
persistence were also counted in shorter-term
persistence (e.g., a man who had a 12-month per-
sistent infection was also counted as a case for 6-
month persistence). Given that persistence was
defined on a type-specific basis, a man could
contribute multiple persistence events. An inter-
mittent negative HPV result between two posi-
tive results (e.g., positive-negative-positive) was
treated as false-negative and, thus, re-assigned as
positive. 
The proportion of men with persistence of dif-
ferent durations was calculated using the number
of men who were positive for an HPV type of in-
terest at the baseline or during follow-up (exclud-
ing infection detected at the last documented visit)
as the denominator. The proportion thus represent-
ed the percent of men who developed persistent in-
fection among those who were ever infected with
the corresponding HPV type during the study peri-
od. The Kaplan-Meier method was applied to esti-
mate median durations of persistence and its 95%
confidence intervals for any, oncogenic and non-
oncogenic HPV infections. The difference in the
median duration of persistence between oncogenic
and non-oncogenic HPV infections was considered
statistically significant in the presence of non-over-
lapping 95% confidence intervals. Estimates were
obtained for persistent infections detected in any
sample (penile, urethral or semen sample) and in
each type of sample, respectively. The associations
between HPV persistence and baseline risk factors
were assessed through univariate analysis in which
the Kaplan-Meier survival probabilities stratified
by individual risk factors were compared using the
log-rank test (p-value < 0.05 statistically signifi-
cant). All statistical analyses were performed in
SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and
Stata/MP v. 11.2 (StataCorp LP, College Station,
TX, USA).
Results
Of 65 men positive for genital HPV at the
baseline, 50 were enrolled in the study, corre-
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sponding to a 77% participation rate. On average
each participant contributed 3.4 visits, amounting
to 170 total visits. The median follow-up time
was 14.7 months (range: 4.8-26.9). The subse-
quent loss to follow-up was 6%. Characteristics
of the study participants are shown in Table I. 
The mean age of participants at enrolment was
34.6 years (median: 33.0; range: 20-60). The ma-
jority of men reported > 5 lifetime sex partners
(72%), having a current partner for 12 months or
longer (56%), and were current smokers (58%).
Seven men (14%) had exophytic genital warts.
The majority of men were sexual partners of
women with confirmed cervical HPV infection
(86%). There were no differences between the
study participants and the 15 men who declined
participation – by age, HPV status in sexual part-
ner, having a current sexual partner, or presence
of external genital warts in men or in sexual part-
ner; however, the groups did differ somewhat by
reported history of sexually transmitted disease,
with non-participants being more likely to report
a sexually transmitted disease (53% vs. 24%; p =
0.05).
The rate of persistence of different durations
for group and type-specific HPV infections is
shown in Table II. With all genital samples com-
bined, persistent infection of ≥ 6, 12, 18 and 24
months with any HPV type was detected in 49%,
36%, 26% and 11% of participants, respectively.
Oncogenic HPV infections were more likely to
persist than non-oncogenic infections for ≥ 6, 12
and 18 months or longer (61% vs. 27%, p =
0.006; 45% vs. 19%, p = 0.0279; and 34% vs.
12%; p = 0.0422, respectively); whereas the like-
lihood of 24-month persistent infections was
similar between oncogenic and non-oncogenic
infections (11% vs. 12%; p = 0.982). The two
most common oncogenic HPV types that persist-
ed for ≥ 24 months were HPV-18 (50%) and
HPV-51 (15%); the two most common non-
oncogenic types were HPV-11 (25%) and HPV-6
(22%). When examined by sample type, there
were no statistically significant differences in
any HPV persistence by anatomical site/fluid at
≥ 6, 12, 18 and 24 months. 
Figure 1 (A-D) describes durations of persis-
tence for any, oncogenic and non-oncogenic
HPV infection detected in any sample, penile,
urethral and semen samples. The median dura-
tion of persistence for any HPV at any sampling
site was 21.7 months (95% CI: 19.0-24.4), with
36% of infections remaining persistent at 24
months after initial HPV detection. Median dura-
tions were not statistically different between
oncogenic persistence (22.5 months; 95% CI:
19.1-25.9) and non-oncogenic persistence (18.4
months; 95% CI: 14.1-22.7). While the median
duration of persistence appeared to be longer for
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Variable n (%)
Age, years
20-34 31 (62.0)
35-60 19 (38.0)
Age at sexual debut
≤ 16 19 (38.0)
17-20 30 (60.0)
> 20 1 (2.0)
Current sexual partner
No 9 (18.0)
Yes 41 (82.0)
Duration of current relationship, years
No relationship 9 (18.0)
≤ 1 13 (26.0)
> 1 28 (56.0)
Lifetime number of sexual partners
≤ 5 14 (28.0)
> 5 36 (72.0)
Recent risky sexual behavioura
No 38 (76.0)
Yes 12 (24.0)
Condom use
Never 11 (22.0)
Sometimes 30 (60.0)
Always 9 (18.0)
Engage in oral sex
No 10 (20.0)
Yes 40 (80.0)
History of sexually transmitted infection
No 38 (76.0)
Yes 12 (24.0)
Presence of  external genital warts
No 43 (86.0)
Yes 7 (14.0)
Presence of external genital
warts in sexual partner
No 45 (90.0)
Yes 5 (10.0)
Confirmed HPV infection in 
sexual partner
No 7 (14.0)
Yes 43 (86.0)
Smoking status
Never 17 (34.0)
Former 4 (8.0)
Current 29 (58.0)
Current alcohol use
No 13 (26.0)
Yes 37 (74.0)
Table I. Baseline characteristics of men (n = 50), Palermo,
Italy, 2006-2009.
aDefined as having sexual intercourse with a casual acquain-
tance without condoms, while under the influence of alco-
hol/drugs.
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Figure 1. Continued
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Figure 1. Duration of persistence for any, oncogenic and non-oncogenic HPV infection detected in any and individual genital
samples.
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penile infections than infections at any other site,
a statistically significant difference was only ob-
served in the median duration of any HPV persis-
tence between penile samples (22.5 months, 95%
CI: 18.3-26.7) and semen samples (15.3 months;
95% CI: 14.5-16.1). 
With all genital samples combined, socio-be-
havioural factors were not associated with type-
specific persistence of any HPV at ≥ 6, 12, 18, or
24 months (data not shown).
Discussion
This prospective cohort study investigated HPV
persistence among men with a prevalent genital
HPV infection detected at the baseline, over a 2-
year study period. Taking into account the difficul-
ty in confirming HPV clearance status in an HPV
natural history study, negative status after having
baseline HPV positive status was best defined in
this study by the absence of HPV DNA detection
in all of three genital sites examined, namely, pe-
nile surface, urethra and semen. On the other hand,
a positive HPV status was ascertained by employ-
ing a combined use of two highly sensitive molec-
ular HPV assays, to assess the full spectrum of in-
fecting types and low-level HPV infections18,19.
Genital HPV persistence is common among
this group of men. With all genital samples com-
bined, 49% of men had a genital HPV infection
that lasted at least 6 months, while infection in
36%, 26% and 11% of men persisted for 12, 18
and 24 months or longer, respectively. 
Only a few epidemiological studies on HPV
persistence in men included DNA samples from
multiple anatomic sites. Giuliano et al17,21 em-
ployed HPV sampling and DNA detection meth-
ods similar to those used in the present analysis,
and reported comparable persistence rates with
6-month persistence observed in 44.5% of initial
infection, 12-month persistence in 25.2% and 18-
month persistence in 10.7% of initial infection. A
slightly lower rate of 6-month persistence was
reported in Danish soldiers by Kjaer et al10. De-
spite differences in sampling protocols, partici-
pant demographic or behavioural profiles or the
use of HPV DNA detection methods with differ-
ent sensitivity between studies, various studies
have shown that a 6-month persistent genital in-
fection is very common among men. Given that
the majority of sexual partners of study partici-
pants had confirmed HPV infection at the study
baseline, it is difficult to determine the original
source of infection within the relationship. How-
ever, persistent infection among study partici-
pants, regardless of anatomical sites that harbour
the virus, will undoubtedly increase the likeli-
hood of future transmission to their sexual part-
ners and impact on their partners’ risk of HPV-
associated diseases. This finding supports the
public health importance of preventing HPV in-
fection in men as a potential source of infection
for their sexual partners using effective measures
such as HPV vaccination.
This study found that oncogenic genital HPV
infection was more likely to persist for 6 months
or longer than non-oncogenic genital HPV infec-
tion (61% and 27%, respectively), whereas the
likelihood of 24-month persistence was similar
between oncogenic and non-oncogenic infection
(11% and 12%, respectively). This finding was
consistent with that of Giuliano et al13, who
found that rates of 6-, 12- and 18-month persis-
tent infections were 41.7%, 19.0% and 0% for
oncogenic HPV types, respectively, compared to
46.5%, 29.3% and 14.4%, respectively, for non-
oncogenic types. This aspect of genital HPV in-
fection in men is different from what has been
shown in cervical HPV infection in women,
which is characterised by a longer duration of in-
fection with oncogenic HPV types, compared
with non-oncogenic types22.
Sampling multiple anatomic sites in men is
considered as the best sampling strategy14,16 to in-
crease the likelihood of HPV DNA detection in
the male external genital area. However, we
found that the rates of persistence for any HPV
or individual HPV type were comparable be-
tween three anatomic sites that we sampled, al-
though more HPV genotypes were detected in
penile samples than urethral or seminal samples.
Thus, our data suggest that sampling of multiple
genital sites may not be required for measuring
the persistence of HPV infection in men, and any
of the three genital samples (penile, urethral or
semen sample) could be used for assessing dura-
tion of genital HPV persistence.
When combining any genital site and any
HPV genotype, a mean duration of 21.7-month
persistence was observed in this study. This val-
ue is different from that reported in other studies,
which is in the range 5.9-7.5 months13,23. One
likely explanation is the fact that approximately
86% of the study cohort consisted of male part-
ners of women with cervical HPV infection, who
might have contributed to the HPV (re) infection
of their male partners. 
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When examining which genital site was more
prone to a longer duration of infection, an in-
creased duration was observed in penile samples
(22.5 months) compared to seminal samples
(15.3 months). The presence of HPV DNA in se-
men for more than one year merits particular at-
tention. Recent studies24,25 reported HPV DNA
presence in spermatozoa, Sertoli and Leydig
cells26 and the vas deferens27, leading to a hy-
pothesized role for HPV infection in male infer-
tility16,24 as well as unfavourable reproductive
outcomes in infertile couples undergoing in vitro
fertilization procedures28.
The lack of association of duration of persistence
with socio-behavioural factors in men was in agree-
ment with findings from a previous study13. Cir-
cumcision seems to be associated with reduced per-
sistence in men9,29,30, even though the mechanism of
protection is unclear. Since this practice is not com-
mon in our geographical area and then in our study
sample, the effect of circumcision on the duration
of HPV infection could not be examined in this
study. Further research is required to determine
whether long-term HPV infection is associated with
impairment in host immune responses or hetero-
geneity in virus-host interactions, as well as to eval-
uate the important role of the sexual partner in the
viral dynamics of genital HPV infection in men.
This study’s unique place in the literature is that
the majority of participants were in a relationship
with a female with confirmed cervical HPV infec-
tion, and therefore the study documents persis-
tence at the penis/urethra/semen in men who are at
high risk for new HPV infections. A limitation of
this report is that the cohort was derived from a
highly selective population, and the estimates of
persistence are not representative of the general
population and may not be generalizable. More-
over, the small sample size of this paper limited
our ability to perform further analysis on persis-
tence of individual HPV types, such as assessing
the duration of persistence and the impact of co-
infection on the duration of persistence.
In 2006, the US Food and Drug Administra-
tion approved the first prophylactic HPV vac-
cine, to be used for young women before sexual
debut; in 2011 it approved the use of HPV vac-
cines for anal cancer prevention in men.
Conclusions
Since HPV vaccination is gaining increasing
attention as a potential preventive approach also
for men, it is imperative to obtain additional in-
sight from studies on natural history of HPV in-
fection in men, particularly as far as incidence
and duration are concerned. 
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